TREM2 and dementia: While further investigation is certainly required to establish effective PBMC biomarkers for clinical use, akin to ongoing investigations in lymphocyte/monocyte ratios [79], dynamic changes in monocyte composition (TREM2+ and classical/nonclassical monocytes) may serve as an accessible, transdiagnostic node for dementia monitoring and prediction.